ArticleStem cell reviews and reports2020

A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.

Rupal P Soder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.